Eli Lilly aims to invest in ‘big problems hiding in plain sight' using obesity windfall
Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...
From pills to new uses, here's what Eli Lilly's top scientist sees as the future of weight ...
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.
The Associated Press - Business News on MSN17 天
Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast. Sales of ...
Lilly Sells $6.5 Billion of Bonds for Cancer Drug Purchase
Eli Lilly & Co. is tapping the U.S. investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase ...
BioPharma Dive17 天
Eli Lilly’s earnings, shares lifted by obesity drug sales
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...
NBC Los Angeles3 天
Eli Lilly aims to invest in ‘big problems hiding in plain sight' using obesity windfall
Eli Lilly's GLP-1 drugs Mounjaro and Zepbound ... Lilly Institute for Genetic Medicine in Boston, away from Lilly's headquarters in Indianapolis and in one of the U.S. epicenters for this work.